Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.06
CFN's Cash to Debt is ranked higher than
67% of the 309 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.81 vs. CFN: 1.06 )
CFN' s 10-Year Cash to Debt Range
Min: 0.56   Max: No Debt
Current: 1.06

Equity to Asset 0.56
CFN's Equity to Asset is ranked higher than
67% of the 298 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. CFN: 0.56 )
CFN' s 10-Year Equity to Asset Range
Min: 0.56   Max: 0.65
Current: 0.56

0.56
0.65
Interest Coverage 8.14
CFN's Interest Coverage is ranked higher than
56% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.96 vs. CFN: 8.14 )
CFN' s 10-Year Interest Coverage Range
Min: 4.1   Max: 10.83
Current: 8.14

4.1
10.83
F-Score: 6
Z-Score: 2.39
M-Score: -2.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 17.44
CFN's Operating margin (%) is ranked higher than
88% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.30 vs. CFN: 17.44 )
CFN' s 10-Year Operating margin (%) Range
Min: 12.01   Max: 17.44
Current: 17.44

12.01
17.44
Net-margin (%) 10.85
CFN's Net-margin (%) is ranked higher than
82% of the 294 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.98 vs. CFN: 10.85 )
CFN' s 10-Year Net-margin (%) Range
Min: 4.94   Max: 14.67
Current: 10.85

4.94
14.67
ROE (%) 7.15
CFN's ROE (%) is ranked higher than
73% of the 291 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.68 vs. CFN: 7.15 )
CFN' s 10-Year ROE (%) Range
Min: 4.12   Max: 13.13
Current: 7.15

4.12
13.13
ROA (%) 4.50
CFN's ROA (%) is ranked higher than
75% of the 299 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.50 vs. CFN: 4.50 )
CFN' s 10-Year ROA (%) Range
Min: 2.44   Max: 7.96
Current: 4.5

2.44
7.96
ROC (Joel Greenblatt) (%) 77.09
CFN's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 297 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. CFN: 77.09 )
CFN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 38.5   Max: 77.09
Current: 77.09

38.5
77.09
Revenue Growth (%) -3.50
CFN's Revenue Growth (%) is ranked higher than
62% of the 276 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.70 vs. CFN: -3.50 )
CFN' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -3.5
Current: -3.5

EBITDA Growth (%) 7.40
CFN's EBITDA Growth (%) is ranked higher than
74% of the 238 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.40 vs. CFN: 7.40 )
CFN' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 7.4
Current: 7.4

0
7.4
EPS Growth (%) 34.20
CFN's EPS Growth (%) is ranked higher than
92% of the 242 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.20 vs. CFN: 34.20 )
CFN' s 10-Year EPS Growth (%) Range
Min: 0   Max: 34.2
Current: 34.2

0
34.2
» CFN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CFN Guru Trades in Q3 2013

Paul Tudor Jones 100,000 sh (New)
Jim Simons 1,509,000 sh (New)
Diamond Hill Capital 89,668 sh (+33.31%)
Joel Greenblatt 195,743 sh (+8.21%)
Jeremy Grantham 17,056 sh (+0.59%)
Vanguard Health Care Fund 4,970,354 sh (unchged)
Robert Olstein 163,000 sh (-6.32%)
Steven Romick 4,325,000 sh (-9.79%)
First Pacific Advisors 4,539,600 sh (-10.06%)
Pioneer Investments 648,830 sh (-31.11%)
Steven Cohen 54,815 sh (-72.74%)
» More
Q4 2013

CFN Guru Trades in Q4 2013

Steven Cohen 683,742 sh (+1147.36%)
Paul Tudor Jones 238,700 sh (+138.7%)
Robert Olstein 219,000 sh (+34.36%)
Diamond Hill Capital 98,438 sh (+9.78%)
Joel Greenblatt 205,291 sh (+4.88%)
First Pacific Advisors 4,551,800 sh (+0.27%)
Vanguard Health Care Fund 4,970,354 sh (unchged)
Steven Romick 4,325,000 sh (unchged)
Jeremy Grantham 14,556 sh (-14.66%)
Pioneer Investments 339,644 sh (-47.65%)
Jim Simons 487,600 sh (-67.69%)
» More
Q1 2014

CFN Guru Trades in Q1 2014

Ray Dalio 22,200 sh (New)
Diamond Hill Capital 213,940 sh (+117.33%)
Robert Olstein 222,000 sh (+1.37%)
First Pacific Advisors 4,568,100 sh (+0.36%)
Vanguard Health Care Fund 4,970,354 sh (unchged)
Steven Romick 4,325,000 sh (unchged)
Jim Simons Sold Out
Pioneer Investments Sold Out
Jeremy Grantham Sold Out
Steven Cohen 465,370 sh (-31.94%)
Joel Greenblatt 41,513 sh (-79.78%)
Paul Tudor Jones 18,292 sh (-92.34%)
» More
Q2 2014

CFN Guru Trades in Q2 2014

Louis Moore Bacon 109,695 sh (New)
Larry Robbins 1,909,705 sh (New)
Jim Simons 125,000 sh (New)
Paul Tudor Jones 361,300 sh (+1875.18%)
Vanguard Health Care Fund 5,661,354 sh (+13.9%)
Diamond Hill Capital 242,594 sh (+13.39%)
Steven Cohen 47,800 sh (unchged)
Ray Dalio Sold Out
Robert Olstein 208,000 sh (-6.31%)
First Pacific Advisors 3,801,500 sh (-16.78%)
Steven Romick 3,580,000 sh (-17.23%)
Joel Greenblatt 4,642 sh (-88.82%)
» More
» Details

Insider Trades

Latest Guru Trades with CFN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Reduce -88.82%0.02%$38.16 - $44.37 $ 45.3610%4642
Ray Dalio 2014-06-30 Sold Out 0.01%$38.16 - $44.37 $ 45.3610%0
Joel Greenblatt 2014-03-31 Reduce -79.78%0.15%$38.52 - $41.71 $ 45.3612%41513
Ray Dalio 2014-03-31 New Buy0.01%$38.52 - $41.71 $ 45.3612%22200
Lee Ainslie 2013-06-30 Sold Out 0.67%$33.21 - $38.17 $ 45.3628%0
Joel Greenblatt 2013-06-30 Add 53.73%0.1%$33.21 - $38.17 $ 45.3628%180890
Joel Greenblatt 2013-03-31 Add 137.86%0.12%$28.58 - $34.99 $ 45.3642%117665
Lee Ainslie 2012-12-31 Reduce -68.04%1.43%$26.54 - $29.05 $ 45.3664%1811353
Joel Greenblatt 2012-12-31 Add 37.36%0.02%$26.54 - $29.05 $ 45.3664%49469
Lee Ainslie 2012-09-30 Reduce -37.47%1.27%$24.01 - $28.63 $ 45.3674%5666718
Joel Greenblatt 2012-09-30 Reduce -65.35%0.13%$24.01 - $28.63 $ 45.3674%36014
John Keeley 2012-09-30 Sold Out 0.11%$24.01 - $28.63 $ 45.3674%0
Lee Ainslie 2012-06-30 Add 6.35%0.2%$23.9 - $27.1 $ 45.3679%9062564
Joel Greenblatt 2012-06-30 Add 379.76%0.16%$23.9 - $27.1 $ 45.3679%103931
Dodge & Cox 2012-06-30 Sold Out 0.01%$23.9 - $27.1 $ 45.3679%0
Lee Ainslie 2012-03-31 Add 8.9%0.26%$22.82 - $26.2 $ 45.3696%8521463
Joel Greenblatt 2012-03-31 New Buy0.05%$22.82 - $26.2 $ 45.3696%21663
John Keeley 2012-03-31 Add 30.15%0.02%$22.82 - $26.2 $ 45.3696%186000
Lee Ainslie 2011-12-31 Add 122.58%1.54%$23.11 - $25.97 $ 45.3685%7824682
George Soros 2011-12-31 Sold Out 0.01%$23.11 - $25.97 $ 45.3685%0
Ray Dalio 2011-12-31 Sold Out 0.01%$23.11 - $25.97 $ 45.3685%0
Dodge & Cox 2011-12-31 Reduce -24.19%$23.11 - $25.97 $ 45.3685%183565
Lee Ainslie 2011-09-30 New Buy1.18%$22.26 - $28.14 $ 45.3678%3515524
Dodge & Cox 2011-09-30 Reduce -84.91%0.04%$22.26 - $28.14 $ 45.3678%242140
George Soros 2011-09-30 Add 32.61%$22.26 - $28.14 $ 45.3678%12200
Ray Dalio 2011-09-30 Add 89.2%$22.26 - $28.14 $ 45.3679%27150
Daniel Loeb 2011-06-30 Sold Out 0.85%$26.4 - $29.89 $ 45.3660%0
Dodge & Cox 2011-06-30 Reduce -87.37%0.36%$26.4 - $29.89 $ 45.3660%1604129
Vanguard Health Care Fund 2011-06-30 Add 20.07%0.1%$26.4 - $29.89 $ 45.3660%4284654
John Keeley 2011-06-30 Add 23.69%0.02%$26.4 - $29.89 $ 45.3660%188290
George Soros 2011-06-30 Reduce -67.03%0.01%$26.4 - $29.89 $ 45.3660%9200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.00
CFN's P/E(ttm) is ranked higher than
84% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 34.60 vs. CFN: 23.00 )
CFN' s 10-Year P/E(ttm) Range
Min: 7.6   Max: 39.94
Current: 23

7.6
39.94
P/B 1.70
CFN's P/B is ranked higher than
83% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. CFN: 1.70 )
CFN' s 10-Year P/B Range
Min: 0.88   Max: 1.76
Current: 1.7

0.88
1.76
P/S 2.50
CFN's P/S is ranked higher than
66% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. CFN: 2.50 )
CFN' s 10-Year P/S Range
Min: 0.91   Max: 2.55
Current: 2.5

0.91
2.55
PFCF 15.70
CFN's PFCF is ranked higher than
92% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.20 vs. CFN: 15.70 )
CFN' s 10-Year PFCF Range
Min: 5.39   Max: 35.57
Current: 15.7

5.39
35.57
EV-to-EBIT 14.99
CFN's EV-to-EBIT is ranked higher than
87% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.48 vs. CFN: 14.99 )
CFN' s 10-Year EV-to-EBIT Range
Min: 7   Max: 15.2
Current: 14.99

7
15.2
Shiller P/E 26.60
CFN's Shiller P/E is ranked higher than
84% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9999.00 vs. CFN: 26.60 )
CFN' s 10-Year Shiller P/E Range
Min: 23.27   Max: 27
Current: 26.6

23.27
27
Current Ratio 3.11
CFN's Current Ratio is ranked higher than
80% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.89 vs. CFN: 3.11 )
CFN' s 10-Year Current Ratio Range
Min: 2.55   Max: 5.56
Current: 3.11

2.55
5.56
Quick Ratio 2.74
CFN's Quick Ratio is ranked higher than
82% of the 244 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.84 vs. CFN: 2.74 )
CFN' s 10-Year Quick Ratio Range
Min: 1.98   Max: 4.89
Current: 2.74

1.98
4.89

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 8.80
CFN's Price/Tangible Book is ranked higher than
66% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.39 vs. CFN: 8.80 )
CFN' s 10-Year Price/Tangible Book Range
Min: 3.95   Max: 8.63
Current: 8.8

3.95
8.63
Price/DCF (Projected) 1.00
CFN's Price/DCF (Projected) is ranked higher than
95% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.22 vs. CFN: 1.00 )
CFN' s 10-Year Price/DCF (Projected) Range
Min: 0.78   Max: 0.98
Current: 1

0.78
0.98
Price/Median PS Value 1.60
CFN's Price/Median PS Value is ranked higher than
62% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. CFN: 1.60 )
CFN' s 10-Year Price/Median PS Value Range
Min: 0.66   Max: 1.53
Current: 1.6

0.66
1.53
Price/Graham Number 3.00
CFN's Price/Graham Number is ranked higher than
80% of the 322 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.93 vs. CFN: 3.00 )
CFN' s 10-Year Price/Graham Number Range
Min: 1.43   Max: 3.19
Current: 3

1.43
3.19
Earnings Yield (Greenblatt) 6.70
CFN's Earnings Yield (Greenblatt) is ranked higher than
79% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.40 vs. CFN: 6.70 )
CFN' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.6   Max: 14.3
Current: 6.7

6.6
14.3
Forward Rate of Return (Yacktman) 5.32
CFN's Forward Rate of Return (Yacktman) is ranked higher than
77% of the 260 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.14 vs. CFN: 5.32 )
CFN' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 3.5   Max: 18.2
Current: 5.32

3.5
18.2

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare: » details
Traded in other countries:TCF.Germany
CareFusion Corp., a Delaware corporation was incorporated on January 14, 2009. The Company is a medical technology company that offers products and services in the areas of medication management, infection prevention, operating room effectiveness, respiratory care and surveillance and analytics. Its main product brands include Alaris intravenous ('IV') infusion systems; Pyxis automated medication dispensing and supply management systems; AVEA, Vela and LTV Series respiratory ventilators; ChloraPrep skin antiseptic products; MaxGuard, MaxPlus and SmartSite needle-free IV infusion disposable sets and accessories; V. Mueller and Snowden-Pencer open surgical and laparoscopic instrumentation; AirLife nebulizers, ventilator circuits and other disposables used for providing respiratory therapy; Jaeger and SensorMedics cardiopulmonary diagnostic equipment; and MedMined software and surveillance services. The Company's main competitors in its Medical Systems segment include Baxter International; B. Braun; Fresenius Kabi; Hospira; Omnicell; McKesson; Dräger; and MAQUET. The Company's competitors in its Procedural Solutions segment include 3M; ICU Medical; Becton, Dickinson; Baxter International; B. Braun; Hospira; Smiths Medical; CR Bard; Integra Life Sciences; and Teleflex. The Company's medical devices sold in the United States are subject to the Federal Food, Drug and Cosmetic Act, as implemented and enforced by the United States Food and Drug Administration.
» More Articles for CFN

Headlines

Articles On GuruFocus.com
FPA Crescent Fund Buys CareFusion, Oracle, Health Net, Sells Omnicare, Travelers, Ensco Jul 16 2013 
FPA Crescent Fund Manager Buys 2 New Stocks Jul 12 2013 
How Richard Blum Had the Best-Performing Picks on GuruFocus in the Past Year Dec 13 2012 
First Pacific Advisors Buys ROSE, CFN, HNT, Sells ESV, PETM, WMT Nov 12 2012 
First Pacific Advisors’ Top New Buys Aug 08 2012 
Crescent Fund's Steven Romick Comments on CareFusion Jul 25 2012 
Steven Romick FPA Crescent Fund Quarterly Commentary Jul 25 2012 
Diamond Hill Capital Sees Value in Comcast, VF, CareFusion and Staples Apr 20 2012 
Diamond Hill Capital Buys Comcast Corp, Walt Disney, Alere Inc, Alaska Air Grp, Xl Group, CareFusion Apr 19 2012 
Stocks Cheaper Than When David Einhorn Bought Feb 16 2012 

More From Our Partners
3 Stocks Advancing The Aerospace/Defense Industry Aug 26 2014 - THESTREET

More From Other Websites
CAREFUSION CORP Financials Aug 15 2014
CAREFUSION CORP Files SEC form 10-K, Annual Report Aug 11 2014
CareFusion Q4 Earnings Soar and Beat Expectations Aug 08 2014
CareFusion Launches Application to Help Clinicians Improve Patient Care for Mechanically Ventilated... Aug 08 2014
CareFusion (CFN) Falls Further As It's Water-Logged And Getting Wetter Aug 08 2014
[$$] CareFusion Profit Up, Outlook Strong Aug 07 2014
CareFusion Corp Earnings Call scheduled for 5:00 pm ET today Aug 07 2014
CareFusion Reports Fourth Quarter And Fiscal 2014 Results Aug 07 2014
CAREFUSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Aug 07 2014
CareFusion Reports Fourth Quarter And Fiscal 2014 Results Aug 07 2014
Q4 2014 CareFusion Corporation Earnings Release - After Market Close Aug 07 2014
Will CareFusion Corp. (CFN) Miss Earnings Estimates? Aug 05 2014
Terrance H. Gregg, the CEO of Dexcom, Inc. (DXCM), Interviews with The Wall Street Transcript Aug 01 2014
CareFusion Launches New ChloraPrep® Applicator For Smaller Coverage Areas Jul 31 2014
CareFusion Launches New ChloraPrep® Applicator For Smaller Coverage Areas Jul 31 2014
Bulls like CareFusion before report Jul 30 2014
Intuitive Surgical Bottom Seen As Procedures Rise Jul 23 2014
FDA sends warning letter to CareFusion after plant inspection Jul 22 2014
CareFusion To Report Fourth Quarter And Fiscal 2014 Results On Aug. 7 Jul 10 2014
CareFusion To Report Fourth Quarter And Fiscal 2014 Results On Aug. 7 Jul 10 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK